Hologic, Inc. (HOLX) Updates FY17 Earnings Guidance
Hologic, Inc. (NASDAQ:HOLX) updated its FY17 earnings guidance on Wednesday. The company provided earnings per share guidance of $1.98-2.02 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.98. The company issued revenue guidance of $3.05-3.08 billion, compared to the consensus revenue estimate of $3.06 billion.Hologic also updated its Q3 guidance to $0.48-0.50 EPS.
A number of research firms recently commented on HOLX. Canaccord Genuity reaffirmed a buy rating and set a $53.00 price target on shares of Hologic in a research note on Tuesday. Leerink Swann reaffirmed an outperform rating and set a $52.00 price target on shares of Hologic in a research note on Thursday, March 30th. Piper Jaffray Companies reaffirmed an overweight rating and set a $51.00 price target on shares of Hologic in a research note on Tuesday, March 14th. Needham & Company LLC lifted their price target on shares of Hologic from $46.00 to $50.00 and gave the stock a buy rating in a research note on Tuesday, April 4th. Finally, Zacks Investment Research cut shares of Hologic from a buy rating to a hold rating in a research note on Friday, February 3rd. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Hologic has a consensus rating of Buy and an average target price of $47.50.
Shares of Hologic, Inc. (NASDAQ:HOLX) traded up 0.86% during midday trading on Wednesday, reaching $45.96. 5,076,990 shares of the company were exchanged. Hologic, Inc. has a 52 week low of $32.64 and a 52 week high of $46.05. The firm has a market capitalization of $12.84 billion, a P/E ratio of 39.28 and a beta of 1.10. The firm has a 50-day moving average of $43.30 and a 200 day moving average of $40.48.
In other Hologic news, Director Lawrence M. Levy sold 10,374 shares of the stock in a transaction that occurred on Wednesday, April 26th. The shares were sold at an average price of $44.46, for a total transaction of $461,228.04. Following the sale, the director now directly owns 37,377 shares in the company, valued at approximately $1,661,781.42. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Lawrence M. Levy sold 10,203 shares of the stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $45.00, for a total transaction of $459,135.00. Following the sale, the director now owns 38,832 shares in the company, valued at $1,747,440. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,639 shares of company stock worth $3,700,697. 0.79% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Updates FY17 Earnings Guidance” was reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/05/10/hologic-inc-holx-updates-fy17-earnings-guidance.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.